Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial.

    ... The phase III AZA-001 study established that azacitidine significantly improves overall survival compared with ... disease progression). Achieving an Overall Response with azacitidine reduced risk of death by 95% compared with achieving an Overall ...

    Research Article last updated 05/14/2013 - 2:51pm.

  2. A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure

    ... Survival after azacitidine (AZA) failure in higher-risk myelodysplastic syndromes (MDS) ...

    Research Article last updated 01/20/2015 - 1:14pm.

  3. Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.

    ... Outcome of patients with myelodysplastic syndrome after azacitidine failure is poor. In this population, we combined cytarabine ...

    Research Article last updated 09/03/2013 - 12:32pm.

  4. Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: a practice standard for Canadian nurses

    ... von Riedemann S, Kurtin S; Canadian Nurses Working Group on Azacitidine in MDS Original ...

    Research Article last updated 03/05/2013 - 9:33am.

  5. Shelf-life Extension of Azacitidine: Waste and Cost Reduction in the Treatment of Myelodysplastic Syndromes

    Journal Title:  Leuk Lymphoma Primary Author:  Guirguis HR Author(s):  Guirgu...

    Research Article last updated 06/19/2014 - 1:26pm.

  6. Real-Life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile

    Journal Title:  Am J Hematol Primary Author:  Breccia M Author(s):  Breccia M...

    Research Article last updated 02/04/2014 - 1:52pm.

  7. Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes

    ... that alter the natural history of the disease. Azacitidine is the only drug reported to improve overall survival in higher ...

    Research Article last updated 09/19/2016 - 11:11am.

  8. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

    Journal Title:  Leukemia Primary Author:  Platzbecker U Author(s):  Platzbeck...

    Research Article last updated 02/04/2013 - 2:29pm.

  9. 5'-Azacitidine in myelodysplastic syndromes with inversion of chromosome 3.

    Journal Title:  Leukemia Primary Author:  Breccia M Author(s):  Breccia M, Ca...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol

    ... Azacitidine treatment is effective in higher risk MDS (HR-MDS), with less ...

    Research Article last updated 09/13/2016 - 2:47pm.